Meeting
2017 Genitourinary Cancers Symposium
Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer.
Authors
Michael Wang
Division of Radiation Oncology, Cross Cancer Institute; Department of Oncology, University of Alberta, Edmonton, AB, Canada
Michael Wang , Robert Pearcey , Nadeem Pervez , Don Yee , Alina Mihai , Samir Patel , John Amanie , Matthew Parliament , Albert Murtha , Sunita Ghosh , Marc Mackenzie , Colin Field , Nawaid Usmani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT00126802
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 56)
DOI
10.1200/JCO.2017.35.6_suppl.56
Abstract #
56
Poster Bd #
C19
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.
First Author: Luca Faustino Valle
Poster
2022 ASCO Genitourinary Cancers Symposium
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.
First Author: David James Carpenter
Poster
2022 ASCO Genitourinary Cancers Symposium
Body fat composition as biomarker for clinical outcomes and treatment tolerance in high-risk prostate cancer.
First Author: Anurag Saraf
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Early experience of combining immune checkpoint inhibitor and radiotherapy in heavily pretreated hepatobiliary cancer.
First Author: Yong Tae Kim